BCR and acute lymphoblastic leukemia: Besides pre-B ALL cells, the inhibitory molecules managed to affect Ph+ ALL cells, especially the ones carrying the Tyrosine Kinase Inhibitor (TKI)-resistant mutant BCR-ABL1T315I, whereas mature B-cell lymphoma and MM cells were significantly less sensitive to treatment [123].